the adaapt tech is the key, they have just sold products of it.
But yes there was money put into development of these products and refining the manufacturing process.
Yes it is cheap, but the best deal you could expect for a company that was in such a poor state.
While they cant make products exactly the same as these, their are still other products that can be developed from the core tech.
- Forums
- ASX - By Stock
- Ann: CardioCel and VascuCel rights sold to LeMaitre Vascular
the adaapt tech is the key, they have just sold products of it....
-
-
- There are more pages in this discussion • 99 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add AVR (ASX) to my watchlist
|
|||||
Last
$15.30 |
Change
-0.380(2.42%) |
Mkt cap ! $323.4M |
Open | High | Low | Value | Volume |
$15.70 | $15.94 | $15.02 | $290.0K | 18.7K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 280 | $15.10 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$15.57 | 779 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 280 | 15.100 |
2 | 96 | 15.020 |
1 | 15 | 15.010 |
2 | 582 | 15.000 |
1 | 1000 | 14.850 |
Price($) | Vol. | No. |
---|---|---|
15.570 | 779 | 1 |
15.930 | 250 | 1 |
15.940 | 554 | 1 |
15.950 | 848 | 2 |
16.000 | 1250 | 2 |
Last trade - 16.10pm 19/08/2024 (20 minute delay) ? |
Featured News
AVR (ASX) Chart |